Little is known regarding the association between level of blood pressure (BP) in young adulthood and cardiovascular disease (CVD) events by middle age.
T he 2017 American College of Cardiology (ACC)/American Heart Association (AHA) blood pressure (BP) guideline defined elevated BP as clinic-measured systolic BP (SBP) of 120 mm Hg to 129 mm Hg and diastolic BP (DBP) less than 80 mm Hg, and stage 1 hypertension as SBP of 130 mm Hg to 139 mm Hg or DBP of 80 mm Hg to 89 mm Hg. 1 These new definitions lowered the BP thresholds for hypertension from SBP/DBP of 140/90 mm Hg or more 2 to SBP/DBP of 130/80 mm Hg or more, 1 and increased the prevalence of hypertension 2-fold to 3-fold among young adults. 1 Nonpharmacological and pharmacological interventions were recommended for adults with stage 1 hypertension who also have an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher. However, most young adults with stage 1 hypertension have low 10-year ASCVD risk and would not be recommended pharmacological interventions. 3 Furthermore, using the Pooled Cohort Equations risk calculator to estimate 10-year ASCVD risk among adults younger than 40 years is not recommended because the equations were developed and validated among adults aged 40 to 79 years. 4 If stage 1 hypertension is not associated with CVD events in young adults, it suggests the possible overdiagnosis of hypertension in this population that could result in unnecessary treatment.
Using data from the Coronary Artery Risk Development in Young Adults (CARDIA) Study, 5 we assessed (1) whether adults who developed elevated BP or hypertension before age 40 years have higher risk for CVD events later in life compared with those who maintained normal BP (SBP <120 mm Hg and DBP <80 mm Hg) through age 40 years; and (2) whether the association differs by race and sex.
Methods
All participants provided written informed consent at each study visit, and institutional review boards at each field center and the coordinating center approved the study annually. The CARDIA study enrolled 5115 African American and white participants aged 18 to 30 years from 4 US field centers (Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California) in 1985 and 1986. 5, 6 The current study excluded participants who experienced CVD events before age 40 years, participants lost to follow-up before age 40 years, and participants who were missing BP data and covariates needed for the analysis. . Semi-annual contact has been maintained with participants for follow-up of events; 87% of the cohort members have participated in a clinic examination or semi-annual interview over the last 2 years; 92% over the last 5 years.
BP and Other Measurements
During the Y 0 to Y 15 examinations, trained research staff measured BP 3 times in participants' right-arm brachial artery at 1-minute intervals after the participant had been sitting in a quiet room for 5 minutes, using a random-zero sphygmomanometer (Hawksley). The mean of the second and third measurements were used for the analysis. The standardized BP measurement techniques using validated equipment in this study met the recommendations in the 2017 ACC/AHA BP guideline to obtain accurate BP measurements in the clinic and are described in the eMethods in the Supplement. An automated oscillometric BP monitor (HEM-907XL; Omron) has been used since the Y 20 examination. A calibration study was performed, and values standardized to the sphygmomanometric measures were used for the Y 20 ,Y 25 ,andY 30 BP measurements (eMethods in the Supplement). 7, 8 The calibration study's alignment of BP values between the 2 measurement devices should minimize potential misclassification of BP levels. CARDIA was specifically designed to study African American and white race/ethnicity differences in the development of cardiovascular risk from young adulthood onwards. Race was determined from responses to closedended questions about the race of each participant's natural mother and father. Other data (including education level, height, weight, smoking status, physical activity, 9 medication use, history of diabetes and CVD, and fasting laboratory values) were collected using standardized protocols and quality control procedures across study centers at each visit, as described previously. 
Cardiovascular Outcomes
Research staff collected information on hospitalizations and outpatient medical procedures during examinations and annual contacts (standardized questionnaires were completed via mail, phone, or email contact). If there were any hospitalizations or outpatient visits, medical records were requested and were used to adjudicate clinical CVD events. Additional semi-annual contacts were conducted (also via mail, phone, or email) and were designed to provide research staff with the opportunity to update participants' contact information. The semi-annual contact also provided an opportunity to assess vital status (the questionnaire on hospitalizations and outpatient medical procedures was not used at this contact). Vital status was also ascertained through periodic searches of the National Death Index. The primary outcome was composite CVD events (fatal and nonfatal coronary heart disease [CHD], hospitalization for heart failure, stroke, transient ischemic attack, or intervention for peripheral artery disease). Definitions of each outcome have been previously described. [10] [11] [12] In the primary analysis, if a participant had more than 1 event occur, the first event was counted as the outcome. In end point-specific analyses (sensitivity analysis), if a participant had more than 1 different type of events, each event was counted as an outcome. For example, if a participant had a diagnosis of CHD and then had a stroke a month later, the CHD and stroke events were counted separately as outcomes in end point-specific analyses. All-cause mortality was examined as a secondary outcome; for this analysis, if a participant had CVD events and then died, her/his death was counted as an outcome. Two physician members of the End Points Committee independently reviewed medical records to adjudicate each possible CVD event or underlying cause of death using specific definitions and a detailed manual of operations (eMethods in the Supplement). 6 For the current analysis, outcomes were available through August 2015.
Statistical Analyses
We calculated characteristics for participants in each of the 4 BP groups (ie, normal BP; elevated BP; stage 1 hypertension; and stage 2 hypertension). We calculated the incidence rate of CVD events and all-cause mortality for participants in each BP group. The cumulative incidence of CVD events and all-cause mortality for the 4 BP groups were calculated using the Kaplan-Meier method. Using Cox proportional hazards models, we estimated the hazard ratios (HRs) and 95% CIs for CVD events associated with the 4 BP groups, separately, with the normal BP group as the referent group. As a post hoc analysis, we fit models for subtypes of CVD events (ie, CHD, stroke, and heart failure), separately. 14 If the proportional hazards assumption was violated, we plotted log-log Kaplan-Meier curves of each BP group to check the points where the curves crossed.
In a sensitivity analysis, to refine the BP groups by requiring 2 or more BP readings for classification of BP stage, participants were categorized as having (1) normal BP at every examination, (2) elevated BP at 2 or more examinations and SBP/DBP less than 130/80 mm Hg at all examinations, (3) stage 1 hypertension at 2 or more examinations and SBP/DBP less than 140/90 mm Hg at all examinations, and (4) stage 2 hypertension at 2 or more examinations. We excluded 119 participants with elevated BP or stage 1 or 2 hypertension at only a single examination from this analysis. All statistical analyses were performed with STATA (StataCorp), version 12.1. Statistical significance was defined as a P value less than .05 using 2-sided tests.
Results
Of the 5115 participants, we excluded 1 participant who withdrew study consent, 19 participants who experienced CVD events before 40 years of age, 13 participants who were lost to follow-up, 220 participants who had BP measurements from only a single examination, and 11 participants who had any missing covariates. The final analytical sample size was 4851 participants (mean age when follow-up began, 35. Participants with elevated BP, stage 1 hypertension, and stage 2 hypertension before age 40 were older, less likely to be women, and more likely to be African American than their counterparts with normal BP ( Table 1) . At the Y 0 examination and when follow-up started, participants in the stage 1 and 2 hypertension groups had higher BMI levels, lower education levels, higher glucose and total cholesterol levels, and lower HDL cholesterol levels compared with the normal BP group (Table 1 ; eTable 1 in the Supplement).
Primary Analysis
During a median follow-up of 18.8 years (IQR, 14.1-20.2), 228 CVD events (CHD, 109; stroke, 63; heart failure, 48; peripheral artery disease, 8) and 319 all-cause deaths occurred. All CVD events and deaths occurred before age 60 years. The cumulative incidence of CVD events was highest in the stage 2 hypertension group, followed by the stage 1 hypertension group, the elevated BP group, and the normal BP group (Figure 1) The proportional hazards assumption tests in model 3 suggested that only the elevated BP group violated the proportional hazards assumption (P < .01). Log-log KaplanMeier curves of the normal BP group and the elevated BP group crossed around a follow-up period of 10 years. For the first 10 years of follow-up, CVD event rates per 1000 personyears were 0.92 for the elevated BP group and 1.23 for the normal BP groups, and the HR (95% CI) for CVD events for Table 3) . In an unadjusted model comparing with normal BP as the referent, stage 2 hypertension before age 40 years was associated with a significantly higher risk of all-cause mortality (HR, 2.82 [95% CI, 2.14-3.71]). This association remained after adjusting for covariates. Elevated BP and stage 1 hypertension were not associated with a higher risk for mortality compared with normal BP. The proportional hazards assumption tests in model 3 yielded no violation (all P > .10). There was no evidence of interaction between BP and race or sex in association with CVD events or all-cause mortality (all P > .10).
Sensitivity Analysis
When participants were categorized in BP groups defined using 2 or more visits with SBP and DBP levels in a category, CVD Log-rank test P <.001
The cumulative probability of CVD events by BP groups were calculated using the Kaplan-Meier method. 
Post Hoc Analysis
During follow-up, the following CVD events occurred: CHD, 114; stroke, 72; transient ischemic attack, 2; heart failure, 66; and peripheral artery disease, 9. The sum of these events (263 events) exceeds the 228 CVD events used in the primary analysis because 30 participants had more than 1 type of events. Event rates and HRs for CHD and stroke events were highest in the stage 2 hypertension group, second-highest in the stage 1 hypertension and elevated BP Log-rank test P <.001
The cumulative probability of all-cause mortality by BP groups were calculated using the groups, and lowest in the normal BP group (eTable 3, upper and middle panels, in the Supplement). The event rates and HRs followed a dose-response relationship across stages of hypertension for heart failure events (eTable 3, bottom panel, in the Supplement). The proportional hazards assumption tests of each BP group in all models yielded no violation (all P > .10).
Discussion
In this community-based study of African American and white participants, there was an association between BP before age 40 years, categorized using the BP classification scheme of the 2017 ACC/AHA BP guideline, and incident CVD events and all-cause mortality by middle age. Elevated BP, stage 1 hypertension, and stage 2 hypertension at any time before age 40 years were each associated with a significantly higher risk for CVD events compared with maintaining normal BP. The higher CVD risk associated with elevated vs normal BP was evident after the initial 10 years of follow-up. Stage 2 hypertension was associated with a significantly higher risk for all-cause mortality compared with normal BP. Prior studies have shown prospective associations between clinic-measured BP classification in young adulthood and later-life CVD events in the United States.
15-19
In the Build and Blood Pressure Study, 15 The high prevalence of subclinical CVD might be explained by individuals' higher cumulative exposure to BP from young adulthood to midlife.
23,24
Antihypertensive medication in middle-aged and older adults does not completely mitigate the higher CVD risk among those with high BP compared with their counterparts who maintain normal BP without taking antihypertensive medication. 25 Nonpharmacological and pharmacological interventions in young adults with elevated BP or stage 1 hypertension should lower cumulative exposure to elevated BP from young adulthood to later life, which in turn may reduce the lifetime risk of CVD.
26
Most large-scale outcomes trials of antihypertensive medication enrolled middle-aged and older adults. Studies are needed to determine the optimal antihypertensive treatment strategy for young adults with hypertension (eg, when antihypertensive medication should be started, the effectiveness of low-dose antihypertensive therapy, and the optimal BP treatment goal). Pharmacological treatment with unclear benefit-to-harm ratios over a lifetime may be impractical for young adults. Randomized clinical trials are needed to determine if a treatment benefit can be achieved over a short to moderate time frame in some subgroups of young adults with stage 1 hypertension. Enrolling young adults with a high lifetime risk for CVD may be practical. Because of the consequent amount of time that must pass to accumulate a sufficient number of CVD events, studies of young adults that could use subclinical CVD markers (eg, left ventricular hypertrophy, coronary artery calcium) as primary outcomes would be an initial step toward providing evidence that pharmacological treatments are appropriate for young adults with hypertension.
Strengths of this study include the large, communitybased cohort of white and African American participants; adjudication of suspected cardiovascular outcomes by a panel of physicians using detailed evaluation criteria; high retention; and the standardized data collection protocols and rigorous quality control in this study. The inception of this study was in 1985, widely recognized as the inflection point in the American obesity epidemic. 21 Because of the young age of the participants in this study at inception, all events in these analyses are considered to be premature CVD events and deaths, an important measure of a population's health unavailable in older cohorts.
Limitations
This study has several limitations. First, possible residual confounding, including sodium intake and psychological factors, may be affecting the BP-CVD event associations.
27,28

Research Original Investigation Association Between Young Adult Hypertension and Cardiovascular Events in Middle Age
Second, it remains unclear how BP measurements in this study collected in a highly controlled research setting correspond to BP measurements commonly obtained in a typical clinic setting. Third, antihypertensive medication use by participants younger than 40 years in this study might be higher than usage levels in the general population. 29 Although the reason is unclear, the difference might result from research participation effects (ie, the Hawthorne effect). 30 Fourth, our results may not be generalizable to other racial and ethnic groups (eg, Asian and Hispanic).
Conclusions
Among young adults, those with elevated blood pressure, stage 1 hypertension, and stage 2 hypertension before age 40 years, as defined by the blood pressure classification in the 2017 ACC/ AHA guidelines, had significantly higher risk for subsequent CVD events compared with those with normal blood pressure before age 40 years. The ACC/AHA blood pressure classification system may help identify young adults at higher risk for CVD events. 5. Caffeine, eating, heavy physical activity, smoking, and alcohol intake were proscribed for two hours prior to BP recording.
6. BP measures were made before the physical examination, blood drawing, treadmill test, or any stressful interview.
7. BP measures were made in a separate room, or at minimum, in an area properly screened from all other activity and other participants.
At each examination, research staff measured right-arm brachial artery BP 3 times after the participant had been sitting in a quiet room for 5 minutes. Three measurements were taken at 1-minute interval, and the average of the 2 nd and 3 rd measurements was used for the analysis of office BP. Of these 47 were not misclassified because they were taking medication (31 of these would be stated to be uncontrolled). Of the remaining 64, not taking antihypertensive medication, 15 had either OS>141 or OD>91, so were correctly classified, and 49 were misclassified (but only missed the cutpoint by 1-2 mmHg). Thus the Omron measure, at face value would liberalize by up to 2 mmHg the definition of high BP, increasing the number declared hypertensive by about 1.2% of the 3521 people, from n=788 to n=837.
Data collection
Participants were asked to fast and to abstain from smoking or heavy physical activity for at least 12 hours before each examination. Blood was drawn by venipuncture according to a standard protocol. 3 Total cholesterol and high-density lipoprotein cholesterol were measured enzymatically. Fasting glucose was measured using the hexokinase method.
Information on smoking status and education was collected via standardized protocols and quality control across study centers. Smoking status was defined as current, former, or never by self-report. Leisure-time physical activity was assessed with the CARDIA Physical Activity History Questionnaire, 4 an interviewer-administered self-report of frequency of participation in each of 13 categories of sports and exercise during the previous 12 months. 5 The 13 categories included 8 vigorous-intensity activities (running or jogging; racquet sports; biking; swimming; exercise or dance class; job lifting, carrying, or digging; shoveling or lifting during leisure; and strenuous sports) and 5 moderateintensity activities (nonstrenuous sports, walking and hiking, golfing and bowling, home exercises or calisthenics, and home maintenance or gardening). For each activity, interviewers asked participants the following questions to assess frequency of participation:
1. Did you (do this activity) in the past 12 months for at least 1 hour total time per month?
2. How many months did you do this activity?
3. How many months did you do this activity for at least 'X' hours per week?
X" varied from 2 through 5. An intensity score was assigned to each activity. 6 The exercise score was computed by multiplying the sum of months of infrequent activity plus 3 times the months of frequent activity by intensity of the activity, and summing over all activities; the score was expressed in "exercise units" (EU).
Cardiovascular outcomes
We recorded incident cardiovascular disease (CVD) events through August, 2015. During their scheduled study examinations and telephone interviews, each participant or designated proxy was asked about interim hospital admissions, outpatient procedures, and deaths. Medical records were requested for participants who had been hospitalized or received an outpatient revascularization procedure. Vital status was assessed every 6 months; medical/death records were requested after consent had been obtained from the participants or next of kin. Two physician members of the Endpoints Committee independently reviewed medical records to adjudicate each possible CVD event or underlying cause of death using specific definitions and a detailed manual of operations (http://www.cardia.dopm.uab.edu).
If disagreement occurred between the primary reviewers, the case was reviewed by the full committee. Coronary heart disease (CHD)
included hospitalization for myocardial infarction, acute coronary syndrome with or without evidence of myocardial necrosis, coronary artery revascularization, or CHD death (including fatal myocardial infarction). CVD included fatal and non-fatal CHD, and hospitalization for heart failure, stroke, transient ischemic attack, or intervention for peripheral artery disease. Definitions of each outcome have been previously described. 
